Although treatment with both GC-1 as well as KB2115 resulted in a decrease of hepatic steatosis, the effects on glycaemia and insulin sensitivity were variable and time-, dosage- and agent-dependent [34, 35]. The gene discussed is INS; the disease is fatty liver disease.